Cargando…

The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the main causes of tumor-related deaths worldwide. Due to the lack of obvious early symptoms and the lack of sensitive screening indicators in the early stage of HCC, the vast majority of patients are diagnosed with advanced or metastatic HCC, resulting in di...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Dandan, He, Rongquan, Dang, Yiwu, Wu, Huayu, Feng, Zhenbo, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928415/
https://www.ncbi.nlm.nih.gov/pubmed/33680930
http://dx.doi.org/10.3389/fonc.2020.608257
_version_ 1783659852490342400
author Xiong, Dandan
He, Rongquan
Dang, Yiwu
Wu, Huayu
Feng, Zhenbo
Chen, Gang
author_facet Xiong, Dandan
He, Rongquan
Dang, Yiwu
Wu, Huayu
Feng, Zhenbo
Chen, Gang
author_sort Xiong, Dandan
collection PubMed
description Hepatocellular carcinoma (HCC) is one of the main causes of tumor-related deaths worldwide. Due to the lack of obvious early symptoms and the lack of sensitive screening indicators in the early stage of HCC, the vast majority of patients are diagnosed with advanced or metastatic HCC, resulting in dissatisfactory treatment result. Therefore, it is urgent to determine effective and sensitive diagnostic and prognostic indicators and to determine new therapeutic targets. Circular RNA (circRNA) is a type of non-coding RNA that has been neglected for a long time. In recent years, it has been proved to play an important role in the development of many human diseases. Increasing evidence shows that change in circRNA expression has an extensive effect on the biological behavior of HCC. In this study, we comprehensively tracked the latest progress of circRNA in the pathogenesis of HCC, and reviewed its role as a biomarker for diagnosis and prognosis prediction in patients with HCC. In addition, we also summarized the potential of circRNA as therapeutic target in HCC and its relationship with HCC drug resistance, providing clues for the clinical development of circRNA-based therapeutic strategies.
format Online
Article
Text
id pubmed-7928415
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79284152021-03-04 The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma Xiong, Dandan He, Rongquan Dang, Yiwu Wu, Huayu Feng, Zhenbo Chen, Gang Front Oncol Oncology Hepatocellular carcinoma (HCC) is one of the main causes of tumor-related deaths worldwide. Due to the lack of obvious early symptoms and the lack of sensitive screening indicators in the early stage of HCC, the vast majority of patients are diagnosed with advanced or metastatic HCC, resulting in dissatisfactory treatment result. Therefore, it is urgent to determine effective and sensitive diagnostic and prognostic indicators and to determine new therapeutic targets. Circular RNA (circRNA) is a type of non-coding RNA that has been neglected for a long time. In recent years, it has been proved to play an important role in the development of many human diseases. Increasing evidence shows that change in circRNA expression has an extensive effect on the biological behavior of HCC. In this study, we comprehensively tracked the latest progress of circRNA in the pathogenesis of HCC, and reviewed its role as a biomarker for diagnosis and prognosis prediction in patients with HCC. In addition, we also summarized the potential of circRNA as therapeutic target in HCC and its relationship with HCC drug resistance, providing clues for the clinical development of circRNA-based therapeutic strategies. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7928415/ /pubmed/33680930 http://dx.doi.org/10.3389/fonc.2020.608257 Text en Copyright © 2021 Xiong, He, Dang, Wu, Feng and Chen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xiong, Dandan
He, Rongquan
Dang, Yiwu
Wu, Huayu
Feng, Zhenbo
Chen, Gang
The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
title The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
title_full The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
title_fullStr The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
title_full_unstemmed The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
title_short The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
title_sort latest overview of circrna in the progression, diagnosis, prognosis, treatment, and drug resistance of hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928415/
https://www.ncbi.nlm.nih.gov/pubmed/33680930
http://dx.doi.org/10.3389/fonc.2020.608257
work_keys_str_mv AT xiongdandan thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT herongquan thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT dangyiwu thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT wuhuayu thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT fengzhenbo thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT chengang thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT xiongdandan latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT herongquan latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT dangyiwu latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT wuhuayu latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT fengzhenbo latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma
AT chengang latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma